论文部分内容阅读
目的:探讨表皮生长因子受体(EGFR),生存素(Survivin)和尿激酶型纤溶酶原激活剂(uPA)在乳腺良、恶性肿瘤表达的意义和它们的相关性。方法:利用PV免疫组织化学方法,检测88例乳腺癌和32例乳腺腺瘤中EGFR,Survivin和uPA阳性率。结果:乳腺腺瘤和乳腺癌EGFR阳性率分别为18.75%和63.64%,两者差异有统计学意义(P<0.01);Survivin在乳腺腺瘤和乳腺癌阳性率分别为65.62%和70.45%;uPA在乳腺腺瘤和乳腺癌阳性率分别为31.25%和61.36%,两者差异有统计学意义(P<0.05)。EGFR,Survivin和uPA在分期低(Ⅰ、Ⅱ期)、非浸润型和无转移组阳性率均低于分期高(Ⅲ、Ⅳ期)、浸润型癌和有淋巴结转移组(P<0.05)。结论:EGFR、Survivin和uPA在乳腺癌中表达率较高,而且和乳腺癌的生物学特性有关。检测它们对提示预后和靶向治疗有指导意义。
Objective: To investigate the significance of the expression of epidermal growth factor receptor (EGFR), Survivin and urokinase-type plasminogen activator (uPA) in benign and malignant breast tumors and their correlation. Methods: The positive rates of EGFR, Survivin and uPA in 88 cases of breast cancer and 32 cases of breast adenoma were detected by PV immunohistochemistry. Results: The positive rates of EGFR in breast adenoma and breast cancer were 18.75% and 63.64%, respectively, with statistical significance (P <0.01). The positive rates of Survivin in breast adenoma and breast cancer were 65.62% and 70.45%, respectively. The positive rates of uPA in breast adenoma and breast cancer were 31.25% and 61.36%, respectively, with significant difference (P <0.05). The positive rates of EGFR, Survivin and uPA in stage Ⅰ, Ⅱ, non - invasive and non - metastasis group were significantly lower than those in stage Ⅲ and Ⅳ, invasive carcinoma and lymph node metastasis group (P <0.05). Conclusion: The expression of EGFR, Survivin and uPA in breast cancer is high, and it is related to the biological characteristics of breast cancer. Detecting them has implications for prognosis and targeted therapy.